Close
CDMO Safety Testing 2026
Novotech

News

ASLAN, Thermo Fisher Join To Manufacture High Concentration Formulation Of Eblasakimab

ASLAN Pharmaceuticals , a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, and Thermo Fisher Scientific Inc, the world leader in serving science, today announced a partnership to manufacture a high concentration formulation of...

Hong Kong University Develops Bone Anabolic Therapy Aptamer

The molecular target for bone anabolic therapy has been discovered by a research team headed by Hong Kong Baptist University (HKBU), utilising a particular aptamer that acts as an inhibitor of sclerostin, a protein that inhibits bone development. In comparison...

Nykode Therapeutics and Richter-Helm BioLogics Enter Manufacturing Partnership

Nykode Therapeutics, a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, has entered into a manufacturing partnership with Richter-Helm BioLogics to supply plasmid DNA for Nykodeโ€™s wholly owned and partnered product portfolio. โ€œWe are excited about...

NHS Cancer Treatment Rates Highest Ever Recorded In 2022

The NHS has released encouraging statistics regarding cancer rates in the UK to kick off the new year. Over the past year, more patients than ever before the pandemic received essential NHS cancer treatments. Furthermore, the number of people...

Antibiotic Resistance Being Weakened By Persistent Bacteria

Researchers from Uppsala University in Sweden have released a study on how various antibiotic treatments affect different types of bacteria and how they respond to such treatments. The study's findings highlight the need for rigorously following antibiotic prescription instructions. According...

CardieX Subsidiary ATCOR Partners with Invaryant to Enable Clinical Trials with Advanced New AI Medical Technology

CardieX Limited, a global health technology company focused on patient-centric healthcare research and improving clinical trial patient outcomes announced a partnership between its ATCOR subsidiary and Invaryant, a data-driven health technology company that empowers individuals with precision AI to...

Japan’s MHLW approves AstraZeneca’s Imfinzi, Imjudo for liver, lung cancers

The Japanese Ministry of Health, Labor, and Welfare (MHLW) has approved AstraZenecaโ€™s immunotherapies Imfinzi (durvalumab) and Imjudo (tremelimumab) to treat advanced liver, biliary tract, and lung cancers. The combination of Imfinzi and Imjudo has been approved to treat unresectable hepatocellular...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate ยป